Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
--(BUSINESS WIRE)--PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, today announced the acquisition of Project ...
Notable treatments include Tezspire, for severe asthma, and Saphnelo, for lupus-related conditions. The company’s future strategy centers on disease modification, expanding treatment options and ...
Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...
A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
Hosted on MSN1mon
Anifrolumab Tied to Less Organ Damage for Patients With LupusT HURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in 2021 WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- Lupus can do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback